OA12629A - 5-HT receptor ligands and uses thereof. - Google Patents
5-HT receptor ligands and uses thereof. Download PDFInfo
- Publication number
- OA12629A OA12629A OA1200300330A OA1200300330A OA12629A OA 12629 A OA12629 A OA 12629A OA 1200300330 A OA1200300330 A OA 1200300330A OA 1200300330 A OA1200300330 A OA 1200300330A OA 12629 A OA12629 A OA 12629A
- Authority
- OA
- OAPI
- Prior art keywords
- tetrahydro
- compound
- benzyloxy
- jbipyrazinyl
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29995301P | 2001-06-21 | 2001-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12629A true OA12629A (en) | 2006-06-14 |
Family
ID=23157027
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200300330A OA12629A (en) | 2001-06-21 | 2002-06-17 | 5-HT receptor ligands and uses thereof. |
OA1200300319A OA12621A (en) | 2001-06-21 | 2002-06-17 | 5-Ht receptor ligands and uses thereof. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200300319A OA12621A (en) | 2001-06-21 | 2002-06-17 | 5-Ht receptor ligands and uses thereof. |
Country Status (39)
Country | Link |
---|---|
US (6) | US6825198B2 (fr) |
EP (2) | EP1401820A1 (fr) |
JP (2) | JP2005501821A (fr) |
KR (2) | KR20040010767A (fr) |
CN (2) | CN1630645A (fr) |
AP (1) | AP2002002561A0 (fr) |
AR (1) | AR036095A1 (fr) |
AU (1) | AU2002309173B2 (fr) |
BG (2) | BG108491A (fr) |
BR (2) | BR0210503A (fr) |
CA (2) | CA2455292A1 (fr) |
CR (1) | CR7168A (fr) |
CZ (2) | CZ20033431A3 (fr) |
DO (1) | DOP2002000412A (fr) |
EA (2) | EA007183B1 (fr) |
EC (2) | ECSP034881A (fr) |
EE (2) | EE200400025A (fr) |
GE (1) | GEP20053655B (fr) |
GT (1) | GT200200120A (fr) |
HR (1) | HRP20031042A2 (fr) |
HU (2) | HUP0400249A3 (fr) |
IL (2) | IL158808A0 (fr) |
IS (2) | IS7041A (fr) |
MA (2) | MA27035A1 (fr) |
MX (2) | MXPA03011940A (fr) |
NO (2) | NO20035697D0 (fr) |
NZ (1) | NZ529542A (fr) |
OA (2) | OA12629A (fr) |
PA (1) | PA8548901A1 (fr) |
PE (1) | PE20030268A1 (fr) |
PL (2) | PL367746A1 (fr) |
SK (2) | SK15712003A3 (fr) |
SV (1) | SV2003001102A (fr) |
TN (2) | TNSN03143A1 (fr) |
UA (1) | UA74443C2 (fr) |
UY (1) | UY27343A1 (fr) |
WO (2) | WO2003000663A1 (fr) |
YU (1) | YU95303A (fr) |
ZA (2) | ZA200308843B (fr) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
CA2462200A1 (fr) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetiques de metallopeptides biologiquement actifs |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US7226925B2 (en) | 2002-06-19 | 2007-06-05 | Biovitrum Ab | Compounds, their use and preparation |
AU2003243089B2 (en) | 2002-06-19 | 2010-01-07 | Biovitrum Ab (Publ) | Novel compounds, their use and preparation |
EA011009B1 (ru) | 2003-01-14 | 2008-12-30 | Арена Фармасьютикалз Инк. | 1,2,3-тризамещённые арильные и гетероарильные производные в качестве модуляторов метаболизма и профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DK1603893T3 (da) * | 2003-01-29 | 2008-09-08 | Asterand Uk Ltd | EP4 -Receptorantagonister |
ES2401330T3 (es) | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
US20040235856A1 (en) * | 2003-04-25 | 2004-11-25 | Pfizer Inc | Treatment of incontinence |
US20080146583A1 (en) * | 2003-05-15 | 2008-06-19 | Pfizer Inc | Treatment of Incontinence |
CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
NZ578503A (en) | 2003-06-17 | 2011-02-25 | Arena Pharm Inc | Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases |
EP2189448B1 (fr) | 2003-06-17 | 2014-01-29 | Arena Pharmaceuticals, Inc. | Procédés de séparation de racemates de 3-Benzazepines |
CN1809545A (zh) * | 2003-06-20 | 2006-07-26 | 艾尼纳制药公司 | N-苯基-哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法 |
AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
AU2004278382B2 (en) * | 2003-09-30 | 2008-09-18 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
US7476687B2 (en) | 2003-11-26 | 2009-01-13 | Alcon, Inc. | Substituted furo[2,3-g]indazoles for the treatment of glaucoma |
US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
EP1694670A1 (fr) * | 2003-12-16 | 2006-08-30 | GPC Biotech AG | Derives de la pyrazine utilises en tant que composes efficaces contre les maladies infectieuses |
WO2005097127A2 (fr) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
EP1756084B1 (fr) * | 2004-06-04 | 2008-11-26 | Arena Pharmaceuticals, Inc. | Derives d'aryle et d'heteroaryle substitues tenant lieu de modulateurs du metabolisme et prevention et traitement de troubles associes |
EP2248524A3 (fr) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci |
US8114502B2 (en) * | 2004-09-02 | 2012-02-14 | 3M Innovative Properties Company | Substrates with multiple images |
AU2005305036B2 (en) * | 2004-11-01 | 2011-03-10 | Amylin Pharmaceuticals, Llc | Treatment of obesity and related disorders |
EP2286837A3 (fr) * | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Traitement de l'obésité et de maladies liés à l'obésité |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
AR051946A1 (es) * | 2004-11-05 | 2007-02-21 | Wyeth Corp | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina |
KR20070086188A (ko) | 2004-11-17 | 2007-08-27 | 미카나 테라퓨틱스, 인크. | 키나제 억제제 |
JPWO2006064780A1 (ja) * | 2004-12-14 | 2008-06-12 | 塩野義製薬株式会社 | 便秘治療剤 |
EP1838677B1 (fr) | 2004-12-21 | 2009-09-09 | Arena Pharmaceuticals, Inc. | Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine |
CA2588941A1 (fr) * | 2004-12-23 | 2006-07-06 | Arena Pharmaceuticals, Inc. | Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants |
AU2006209216A1 (en) * | 2005-01-25 | 2006-08-03 | Galenea Corp | Substituted arylamine compounds and their use as 5-HT6 modulators |
EP1869000A1 (fr) * | 2005-03-31 | 2007-12-26 | Pfizer Products Incorporated | Derives de cyclopentapyridine et de tetrahydroquinoline |
US7594976B2 (en) * | 2005-05-13 | 2009-09-29 | 3M Innovative Properties Company | Methods of manufacturing substrates |
EP2324886A1 (fr) | 2005-07-29 | 2011-05-25 | Concert Pharmaceuticals Inc. | Nouveaux analogues deutériés de tadalafil |
BRPI0616630B8 (pt) * | 2005-09-30 | 2021-05-25 | Miikana Therapeutics Inc | compostos de pirazol substituídos |
AU2006323025B2 (en) * | 2005-12-05 | 2012-07-05 | Pfizer Products Inc. | Polymorphs of a c-Met/HGFR inhibitor |
CA2632286C (fr) * | 2005-12-05 | 2011-11-15 | Pfizer Products Inc. | Utilisation de (r)-3-[1-(2,6-dichloro-3-fluro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine pour le traitement du cancer |
US20070142369A1 (en) * | 2005-12-21 | 2007-06-21 | Margaret Van Heek | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
CN101466684B (zh) | 2006-04-03 | 2012-06-20 | 艾尼纳制药公司 | 8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的制备工艺和其相关中间体 |
JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
US7902184B2 (en) * | 2006-05-30 | 2011-03-08 | Hoffmann-La Roche Inc. | Piperazinyl pyrimidine derivatives |
AU2007274710A1 (en) * | 2006-07-14 | 2008-01-24 | Pfizer Products Inc. | Tartrate salt of (7S)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2R)-2-methylpiperazin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridine |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
KR20090064478A (ko) | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
WO2008058341A1 (fr) * | 2006-11-15 | 2008-05-22 | Cytopia Research Pty Ltd | Inhibiteurs de l'activité kinase |
CA2670285A1 (fr) | 2006-12-05 | 2008-06-12 | Arena Pharmaceuticals, Inc. | Procedes de preparation de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine et intermediaires de celle-ci |
EP2494967A1 (fr) | 2007-01-16 | 2012-09-05 | Ipintl, Llc | Nouvelle composition pour le traitement du syndrôme métabolique |
US20080220104A1 (en) * | 2007-03-08 | 2008-09-11 | Cappello John V | Compositions for producing satiety |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2527360B1 (fr) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
JP2010529193A (ja) * | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
EP2789338A3 (fr) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Dérivé de pyridine condensé et son utilisation |
CN102015591B (zh) * | 2008-03-04 | 2014-01-29 | 艾尼纳制药公司 | 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓相关的中间体的方法 |
CA2727684C (fr) | 2008-06-12 | 2017-01-31 | Janssen Pharmaceutica Nv | Modulateurs de diamino-pyridine, pyrimidine et pyridazine du recepteur de l'histamine h<sb>4</sb> |
WO2009154739A2 (fr) * | 2008-06-17 | 2009-12-23 | Duke University | Modulateurs du récepteur smoothened |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
CA2743489A1 (fr) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Amines bicycliques substituees pour le traitement du diabete |
US8952197B2 (en) | 2009-06-18 | 2015-02-10 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
EP2445899B1 (fr) * | 2009-06-26 | 2016-05-11 | Sanofi | Nouveaux sels fumarates d'un antagoniste des récepteurs h3 de l'histamine |
US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
EP2510949A4 (fr) | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | Agent thérapeutique pour la fibromyalgie |
WO2011106273A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques |
EP2563764B1 (fr) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
WO2011153206A1 (fr) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Procédés pour la préparation d'agonistes du récepteur 5-ht2c |
EP2579873A4 (fr) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | Nouveaux inhibiteurs de prolylcarboxypeptidase |
PL2585216T3 (pl) * | 2010-06-23 | 2020-06-01 | Johnson Matthey Plc | Kompleksy pi-allilopalladowe i pi-alliloniklowe do zastosowania jako katalizatory w reakcjach sprzęgania węgiel-azot |
KR20140091458A (ko) | 2010-09-01 | 2014-07-21 | 아레나 파마슈티칼스, 인크. | 신장 손상을 갖는 개체에 대한 로카세린의 투여 |
KR20130101524A (ko) | 2010-09-01 | 2013-09-13 | 아레나 파마슈티칼스, 인크. | 5-ht2c 아고니스트의 비-흡습성 염 |
AU2011296003B2 (en) | 2010-09-01 | 2015-11-12 | Arena Pharmaceuticals, Inc. | Modified-release dosage forms of 5-HT2C agonist useful for weight management |
CN103189359A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 5-ht2c激动剂的光学活性酸盐 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012040279A1 (fr) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés |
BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
HUE029988T2 (en) * | 2011-02-25 | 2017-04-28 | Yuhan Corp | Diaminopyrimidine derivatives and processes for their preparation |
WO2013178569A1 (fr) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Hétérocycles pyrrolidino |
WO2014022528A1 (fr) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
CA2886875A1 (fr) | 2012-10-09 | 2014-04-17 | Arena Pharmaceuticals, Inc. | Procede de gestion du poids |
CA2897651C (fr) | 2013-01-10 | 2021-09-21 | Pulmokine, Inc. | Inhibiteurs de kinase non selectifs |
AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2014151206A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
WO2014151200A2 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
CA2926793C (fr) | 2013-10-11 | 2022-11-22 | Lawrence S. ZISMAN | Formulations a sechage par pulverisation pour le traitement de l'hypertension arterielle pulmonaire |
WO2015066344A1 (fr) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
CN110087653A (zh) | 2016-10-27 | 2019-08-02 | 普尔莫凯恩股份有限公司 | 用于治疗肺高血压的组合疗法 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (fr) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
BR112021017621A2 (pt) * | 2019-03-07 | 2021-11-23 | Arbormentis LLC | Composições e métodos de uso compreendendo substâncias com ações de plasticidade neural administradas em dosagens e formulações não psicodélicas/psicotomiméticas |
CN111704582B (zh) * | 2020-06-23 | 2021-06-11 | 杭州煌森生物科技有限公司 | 一种法匹拉韦及其衍生物的制备方法 |
CN115618396B (zh) * | 2022-11-28 | 2023-04-07 | 云账户技术(天津)有限公司 | 一种数据的加密方法及装置 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL127996C (fr) | 1963-11-19 | |||
US3980781A (en) * | 1966-03-31 | 1976-09-14 | Imperial Chemical Industries Limited | Fungicidal composition and method containing 2-amino-pyrimidines |
GB1165283A (en) * | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
US4166852A (en) | 1974-08-09 | 1979-09-04 | Produits Chimiques Ugine Kuhlmann | Piperazino-pyrimidines and their use as spasmolytic agents |
FR2281117A2 (fr) | 1974-08-09 | 1976-03-05 | Ugine Kuhlmann | Nouvelles piperazino-pyrimidines utilisables comme medicaments |
US4081542A (en) | 1975-04-21 | 1978-03-28 | Merck & Co., Inc. | Piperazinylpyrazines |
SE421695B (sv) * | 1975-04-21 | 1982-01-25 | Merck & Co Inc | Sett att framstella piperazinylpyraziner |
FR2311776A1 (fr) | 1975-05-23 | 1976-12-17 | Sogeras | Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation |
FI70411C (fi) | 1980-12-29 | 1986-09-19 | Pfizer | Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat |
HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
DE3905364A1 (de) | 1989-02-22 | 1990-08-23 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
JPH0665203A (ja) | 1992-06-25 | 1994-03-08 | Elf Sanofi | ピペラジンのヘテロ環誘導体 |
NZ254550A (en) | 1992-09-28 | 1997-08-22 | Pfizer | Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications |
PL313973A1 (en) | 1993-10-12 | 1996-08-05 | Du Pont Merck Pharma | 1 n-alkyl-n-arylopyrimidin amines and their derivatives |
WO1995010506A1 (fr) * | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyle-n-arylpyrimidinamines et leurs derives |
US5419301A (en) * | 1994-04-14 | 1995-05-30 | Ford Motor Company | Adaptive control of camless valvetrain |
WO1996031488A1 (fr) * | 1995-04-03 | 1996-10-10 | Sumitomo Pharmaceuticals Company, Limited | Nouveaux derives de pyrimidine efficaces en tant que medicament psychotrope et leur procede de fabrication |
US5795905A (en) | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
PT791355E (pt) | 1996-02-29 | 2002-08-30 | Pfizer | Metodo para diminuir os daos associados com a isquemia nos tecidos |
US6326368B1 (en) | 1996-03-27 | 2001-12-04 | Dupont Pharmaceuticals Company | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
KR100239800B1 (ko) * | 1996-11-28 | 2000-03-02 | 손경식 | 4,5-디아미노 피리미딘 유도체 및 이의 제조방법 |
DE19710435A1 (de) | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
WO2000028993A1 (fr) | 1998-11-19 | 2000-05-25 | Nortran Pharmaceuticals, Inc. | Ligands de serotonine en tant que composes favorisant l'erection |
GB9902047D0 (en) | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
BR0010783A (pt) | 1999-05-21 | 2002-04-09 | Biovitrum Ab | Novos compostos, seu uso e preparação |
SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
SE0004245D0 (sv) * | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
EP1335907B1 (fr) | 2000-11-20 | 2010-06-09 | Biovitrum AB (publ) | Composes de piperazinylpyrazine utilises comme agonistes ou antagonistes du recepteur de la serotonine 5ht-2 |
DE60139021D1 (de) | 2000-11-20 | 2009-07-30 | Biovitrum Ab Publ | Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors |
-
2002
- 2002-05-28 US US10/156,884 patent/US6825198B2/en not_active Expired - Fee Related
- 2002-06-05 DO DO2002000412A patent/DOP2002000412A/es unknown
- 2002-06-05 US US10/163,881 patent/US6894050B2/en not_active Expired - Fee Related
- 2002-06-14 GT GT200200120A patent/GT200200120A/es unknown
- 2002-06-17 YU YU95303A patent/YU95303A/sh unknown
- 2002-06-17 JP JP2003507071A patent/JP2005501821A/ja not_active Abandoned
- 2002-06-17 CZ CZ20033431A patent/CZ20033431A3/cs unknown
- 2002-06-17 EE EEP200400025A patent/EE200400025A/xx unknown
- 2002-06-17 WO PCT/IB2002/002261 patent/WO2003000663A1/fr active IP Right Grant
- 2002-06-17 EE EEP200400026A patent/EE200400026A/xx unknown
- 2002-06-17 SK SK1571-2003A patent/SK15712003A3/sk not_active Application Discontinuation
- 2002-06-17 CZ CZ20033508A patent/CZ20033508A3/cs unknown
- 2002-06-17 AU AU2002309173A patent/AU2002309173B2/en not_active Ceased
- 2002-06-17 OA OA1200300330A patent/OA12629A/en unknown
- 2002-06-17 EP EP02735869A patent/EP1401820A1/fr not_active Withdrawn
- 2002-06-17 IL IL15880802A patent/IL158808A0/xx unknown
- 2002-06-17 TN TNPCT/IB2002/002261A patent/TNSN03143A1/fr unknown
- 2002-06-17 NZ NZ529542A patent/NZ529542A/en unknown
- 2002-06-17 IL IL15880702A patent/IL158807A0/xx unknown
- 2002-06-17 TN TNPCT/IB2002/002293A patent/TNSN03142A1/fr unknown
- 2002-06-17 MX MXPA03011940A patent/MXPA03011940A/es active IP Right Grant
- 2002-06-17 EA EA200301215A patent/EA007183B1/ru not_active IP Right Cessation
- 2002-06-17 BR BR0210503-9A patent/BR0210503A/pt not_active IP Right Cessation
- 2002-06-17 KR KR10-2003-7016704A patent/KR20040010767A/ko not_active Application Discontinuation
- 2002-06-17 PL PL02367746A patent/PL367746A1/xx not_active Application Discontinuation
- 2002-06-17 EA EA200301213A patent/EA200301213A1/ru unknown
- 2002-06-17 OA OA1200300319A patent/OA12621A/en unknown
- 2002-06-17 WO PCT/IB2002/002293 patent/WO2003000666A1/fr not_active Application Discontinuation
- 2002-06-17 BR BR0210471-7A patent/BR0210471A/pt not_active IP Right Cessation
- 2002-06-17 KR KR1020037016699A patent/KR100566854B1/ko not_active IP Right Cessation
- 2002-06-17 PL PL02367777A patent/PL367777A1/xx not_active Application Discontinuation
- 2002-06-17 HU HU0400249A patent/HUP0400249A3/hu unknown
- 2002-06-17 JP JP2003507068A patent/JP2004534823A/ja not_active Withdrawn
- 2002-06-17 EP EP02735853A patent/EP1401819A1/fr not_active Withdrawn
- 2002-06-17 MX MXPA03011941A patent/MXPA03011941A/es unknown
- 2002-06-17 GE GE5389A patent/GEP20053655B/en unknown
- 2002-06-17 CN CNA028137345A patent/CN1630645A/zh active Pending
- 2002-06-17 CN CNA028125541A patent/CN1745074A/zh active Pending
- 2002-06-17 CA CA002455292A patent/CA2455292A1/fr not_active Abandoned
- 2002-06-17 UA UA20031211976A patent/UA74443C2/uk unknown
- 2002-06-17 SK SK1567-2003A patent/SK15672003A3/sk unknown
- 2002-06-17 HU HU0400251A patent/HUP0400251A3/hu unknown
- 2002-06-17 CA CA002450491A patent/CA2450491A1/fr not_active Abandoned
- 2002-06-19 AR ARP020102299A patent/AR036095A1/es unknown
- 2002-06-19 PE PE2002000529A patent/PE20030268A1/es not_active Application Discontinuation
- 2002-06-20 AP APAP/P/2002/002561A patent/AP2002002561A0/en unknown
- 2002-06-20 SV SV2002001102A patent/SV2003001102A/es not_active Application Discontinuation
- 2002-06-20 UY UY27343A patent/UY27343A1/es not_active Application Discontinuation
- 2002-06-21 PA PA20028548901A patent/PA8548901A1/es unknown
-
2003
- 2003-11-13 ZA ZA200308843A patent/ZA200308843B/en unknown
- 2003-11-13 ZA ZA200308842A patent/ZA200308842B/en unknown
- 2003-11-17 IS IS7041A patent/IS7041A/is unknown
- 2003-11-17 IS IS7040A patent/IS7040A/is unknown
- 2003-11-25 CR CR7168A patent/CR7168A/es not_active Application Discontinuation
- 2003-12-08 EC EC2003004881A patent/ECSP034881A/es unknown
- 2003-12-09 EC EC2003004884A patent/ECSP034884A/es unknown
- 2003-12-10 MA MA27431A patent/MA27035A1/fr unknown
- 2003-12-10 MA MA27432A patent/MA27036A1/fr unknown
- 2003-12-16 HR HR20031042A patent/HRP20031042A2/hr not_active Application Discontinuation
- 2003-12-19 NO NO20035697A patent/NO20035697D0/no not_active Application Discontinuation
- 2003-12-19 NO NO20035698A patent/NO20035698L/no not_active Application Discontinuation
- 2003-12-22 BG BG108491A patent/BG108491A/xx unknown
- 2003-12-22 BG BG108495A patent/BG108495A/xx unknown
-
2004
- 2004-08-19 US US10/922,058 patent/US20050090503A1/en not_active Abandoned
- 2004-08-19 US US10/922,198 patent/US20050020604A1/en not_active Abandoned
- 2004-09-16 US US10/942,345 patent/US6995159B2/en not_active Expired - Fee Related
- 2004-09-16 US US10/942,346 patent/US20050054656A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA12629A (en) | 5-HT receptor ligands and uses thereof. | |
AU2002309173A1 (en) | 5-HT receptor ligands and uses thereof | |
JP6117816B2 (ja) | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 | |
US7601714B2 (en) | Pyrimidine derivatives useful as inhibitors of PKC-theta | |
WO2006000902A1 (fr) | Composes dihydrobenzofurane et leurs utilisations | |
US20140005393A1 (en) | Sulfonamide compounds having trpm8 antagonistic activity | |
AU2008231543A1 (en) | Pyrimido [4, 5-D] azepine derivatives as 5-HT2C agonists | |
BG108490A (bg) | 5-заместени-2-арилпиридини като модулатори на crf1 | |
US20220332695A1 (en) | Urea derivatives as cb1 allosteric modulators | |
AU2002309183A1 (en) | 5-HT receptor ligands and uses thereof | |
WO2004054981A1 (fr) | Derives de 5-aminophenanthridine servant d'antagonistes de npy-5 | |
CA2690976A1 (fr) | Composes de benzenesulfonamide appropries pour le traitement de troubles qui repondent a une modulation du recepteur d<sb>3</sb> de la dopamine |